공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

위식도접합부선암 : 파이프라인 리뷰

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 11월 상품 코드 257785
페이지 정보 영문 320 Pages
가격
US $ 2,000 ₩ 2,282,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,565,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,848,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


위식도접합부선암 : 파이프라인 리뷰 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016
발행일 : 2016년 11월 페이지 정보 : 영문 320 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

위식도접합부선암은 식도와 위식도 접합부의 암입니다. 증상에는 부전실어증, 체중 감소, 기침, 연하통, 통증, 쉰 목소리 등이 있습니다. 소인은 노화, 비만, 위식도 역류병(GERD), 흡연, 알코올 중독을 들 수 있습니다. 치료에는 화학요법과 방사선 요법이 있습니다.

위식도접합부선암(Adenocarcinoma Of The Gastroesophageal Junction) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

위식도접합부선암 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

위식도접합부선암 : 기업에서 개발중인 치료제

위식도접합부선암 : 대학/기관에서 연구중인 치료제

위식도접합부선암 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

위식도접합부선암 : 기업에서 개발중인 제품

위식도접합부선암 : 대학/기관에서 연구중인 제품

위식도접합부선암 치료제 개발에 참여하고 있는 기업

  • AB Science SA
  • AbbVie Inc.
  • Advenchen Laboratories, LLC
  • Amgen Inc.
  • ArQule, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Cerulean Pharma, Inc.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Ganymed Pharmaceuticals AG
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Hutchison MediPharma Limited
  • Imugene Limited
  • Johnson & Johnson
  • Mebiopharm Co., Ltd.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • Sanofi
  • Taiho Pharmaceutical Co., Ltd.

위식도접합부선암 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

위식도접합부선암 : 최근의 파이프라인 동향

위식도접합부선암 : 휴지중인 프로젝트

위식도접합부선암 : 개발이 중지된 제품

위식도접합부선암 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 16.07.01

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline landscape.

Gastroesophageal (GE) junction adenocarcinomas are carcinomas of the esophagus and the gastro-esophageal junction. Symptoms include dysphasia, weight loss, cough, odynophagia, pain and hoarseness. Risk factors include age, overweight or obese, gastroesophageal reflux disease (GERD), smoking and alcoholism. Treatment includes chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 23, 10 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.Adenocarcinoma Of The Gastroesophageal Junction.

Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Adenocarcinoma Of The Gastroesophageal Junction Overview
  • Therapeutics Development
    • Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview
    • Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis
  • Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies
  • Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Investigation by Universities/Institutes
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies
  • Adenocarcinoma Of The Gastroesophageal Junction - Products under Investigation by Universities/Institutes
  • Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development
    • AB Science SA
    • AbbVie Inc
    • Advenchen Laboratories, LLC
    • Amgen Inc.
    • ArQule, Inc.
    • AstraZeneca Plc
    • Boehringer Ingelheim GmbH
    • Boston Biomedical, Inc.
    • Bristol-Myers Squibb Company
    • Cerulean Pharma, Inc.
    • Daiichi Sankyo Company, Limited
    • Dr. Reddy's Laboratories Limited
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Ganymed Pharmaceuticals AG
    • Genentech Inc
    • Gilead Sciences, Inc.
    • Hutchison MediPharma Limited
    • Imugene Limited
    • Mebiopharm Co., Ltd.
    • MedImmune LLC
    • Merck & Co., Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • Neopharm Ltd.
    • Novartis AG
    • Oncobiologics, Inc.
    • Panacea Biotec Limited
    • Sanofi
  • Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AL-3818 - Drug Profile
    • alpelisib - Drug Profile
    • AMG-337 - Drug Profile
    • atezolizumab - Drug Profile
    • avelumab - Drug Profile
    • AZD-4547 - Drug Profile
    • AZD-6738 - Drug Profile
    • BI-853520 - Drug Profile
    • cabazitaxel - Drug Profile
    • catumaxomab - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • ceritinib - Drug Profile
    • CRLX-101 - Drug Profile
    • DS-8201 - Drug Profile
    • durvalumab - Drug Profile
    • durvalumab + tremelimumab - Drug Profile
    • emibetuzumab - Drug Profile
    • GS-5745 - Drug Profile
    • ibrutinib - Drug Profile
    • IMAB-362 - Drug Profile
    • IMU-131 - Drug Profile
    • ipatasertib - Drug Profile
    • ipilimumab - Drug Profile
    • JS-001 - Drug Profile
    • LAG-525 - Drug Profile
    • LY-3127804 - Drug Profile
    • masitinib - Drug Profile
    • merestinib - Drug Profile
    • napabucasin - Drug Profile
    • nimotuzumab - Drug Profile
    • oxaliplatin - Drug Profile
    • panitumumab - Drug Profile
    • PDR-001 - Drug Profile
    • pembrolizumab - Drug Profile
    • pertuzumab - Drug Profile
    • ramucirumab - Drug Profile
    • SAR-408701 - Drug Profile
    • savolitinib - Drug Profile
    • serabelisib - Drug Profile
    • sonidegib phosphate - Drug Profile
    • tivantinib - Drug Profile
    • trastuzumab biosimilar - Drug Profile
    • trastuzumab biosimilar - Drug Profile
    • trastuzumab biosimilar - Drug Profile
    • trastuzumab biosimilar - Drug Profile
    • trastuzumab biosimilar - Drug Profile
    • tremelimumab - Drug Profile
  • Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects
  • Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products
  • Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016
  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AbbVie Inc, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech Inc, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune LLC, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Neopharm Ltd., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Oncobiologics, Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects (Contd..1), H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016
  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top
전화 문의
F A Q